1. A liquid crystal display panel, comprising:
a first substrate comprising an insulating substrate, a thin film transistor, a scan signal line, a first light-shielding electrode, a first insulating film, a second light-shielding electrode, a second insulating film, a transparent electrode, a third insulating film, and a pixel electrode;
a second substrate comprising an insulating substrate; and
a liquid crystal layer sandwiched between the first substrate and the second substrate,
the second light-shielding electrode being located between the thin film transistor and the pixel electrode and connected to the pixel electrode through a connecting portion formed through the second insulating film and the third insulating film,
the first light-shielding electrode at least partly overlapping with the second light-shielding electrode with the first insulating film therebetween, and
the transparent electrode being in a layer closer to the liquid crystal layer than both a layer including the scan signal line and a layer including the second light-shielding electrode are.
2. The liquid crystal display panel according to claim 1,
wherein the transparent electrode is a common electrode, the common electrode and the pixel electrode generating an electric field in the liquid crystal layer between these electrodes, and
a potential supplied to the first light-shielding electrode is the same as a potential supplied to the transparent electrode.
3. The liquid crystal display panel according to claim 1 which is a normally black liquid crystal display panel,
wherein the second substrate has a common electrode, and
a potential supplied to the first light-shielding electrode is the same as a potential supplied to the common electrode.
4. The liquid crystal display panel according to claim 1 which is a normally white liquid crystal display panel,
wherein the second substrate has a common electrode,
a potential supplied to the first light-shielding electrode is different from a potential supplied to a common potential.
5. The liquid crystal display panel according to claim 1,
wherein the first light-shielding electrode extends substantially parallel to the scan signal line and is in the same layer as the scan signal line.
6. The liquid crystal display panel according to claim 1,
further comprising a data signal line,
wherein the first light-shielding electrode extends substantially parallel to the data signal line and has a portion located in the same layer as the data signal line and a portion located in the same layer as the scan signal line.
7. The liquid crystal display panel according to claim 1,
wherein the first light-shielding electrode and the second light-shielding electrode have an overlapping region comprising a region of at least 5 \u03bcm square.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1.-1120. (canceled)
1121. A method for treating a patient having an aneurysm, comprising delivering to a patient in need thereof a stent graft, wherein the stent graft comprises i) a stent graft and ii) a fibrosing agent or a composition comprising a fibrosing agent, wherein the agent induces fibrosis.
1122. The method of claim 1121 wherein the aneurysm is an aortic aneurysm.
1123. The method of claim 1121 wherein the aneurysm is an abdominal, thoracic, or iliac aortic aneurysm.
1124. The method of claim 1121 wherein the fibrosing agent promotes regeneration.
1125. The method of claim 1121 wherein the fibrosing agent promotes angiogenesis.
1126. The method of claim 1121 wherein the fibrosing agent promotes fibroblast migration.
1127. The method of claim 1121 wherein the fibrosing agent promotes fibroblast proliferation.
1128. The method of claim 1121 wherein the fibrosing agent promotes deposition of extracellular matrix (ECM).
1129. The method of claim 1121 wherein the fibrosing agent promotes tissue remodeling.
1130. The method of claim 1121 wherein the fibrosing agent is an arterial vessel wall irritant.
1131. The method of claim 1121 wherein the fibrosing agent is or comprises silk.
1132. The method of claim 1121 wherein the fibrosing agent is or comprises mineral particles.
1133. The method of claim 1121 wherein the fibrosing agent is or comprises chitosan.
1134. The method of claim 1121 wherein the fibrosing agent is or comprises polylysine.
1135. The method of claim 1121 wherein the fibrosing agent is or comprises fibronectin.
1136. The method of claim 1121 wherein the fibrosing agent is or comprises bleomycin.
1137. The method of claim 1121 wherein the fibrosing agent is or comprises CTGF.
1138.-1140. (canceled)
1141. The method of claim 1121 wherein the composition further comprises an agent that stimulates cell proliferation.
1142.-1187. (canceled)
1188. The method of claim 1121, wherein the stent graft is combined with a second pharmaceutically active agent.
1189. The method of claim 1121, wherein the device comprises further an anti-inflammatory agent.
1190. The method of claim 1121, wherein the device further comprises an agent that inhibits infection.
1191.-1738. (canceled)